

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2008 (10.04.2008)

PCT

(10) International Publication Number
WO 2008/042240 A3

(51) International Patent Classification:

C07F 9/572 (2006.01) *A61P 31/18* (2006.01)
A61K 31/675 (2006.01)

(21) International Application Number:

PCT/US2007/020900

(22) International Filing Date:

28 September 2007 (28.09.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/848,584 29 September 2006 (29.09.2006) US
60/857,980 9 November 2006 (09.11.2006) US
60/903,115 23 February 2007 (23.02.2007) US

(71) Applicant (for all designated States except US): **IDENIX PHARMACEUTICALS, INC.** [US/US]; One Kendall Sq., Bldg 1400, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STORER, Richard** [GB/GB]; Sandgate Point, The Leas, Folkestone, Kent CT20 2JE (GB). **ALEXANDRE, Francois-Rene** [FR/FR]; Residence Occitanie, 200, avenue du Major Flandre, F-34090 Montpellier (FR). **DOUSSON, Cyril** [FR/FR];

Las Rebes, 126, allée Beranger, F-34080 Montpellier (FR). **MOUSSA, Adel, M.** [US/US]; 34 Newbridge Avenue, Burlington, MA 01803 (US). **BRIDGES, Edward** [US/US]; 9 George Road, Maynard, MA 01754 (US).

(74) Agents: **RIEGER, Dale, L.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS

SCHEMATIC STRUCTURE OF HIV-1 K103N/Y181C RT WITH COMPOUND I



(57) Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of *Flaviviridae* virus infections, and particularly for HLV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other antiviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds. The 3-phosphoindole compounds are of the formula (A) or (B) and the pharmaceutically acceptable salts, solvates, hydrates, or esters thereof. In the formulae X is hydrogen; aryl or heterocyclyl; C₂₋₆ alkenyl, C₂₋₆ alkynyl or alkyl; Y is hydrogen, -R, -O-R, -NH-R, or -NRR; Z is -OR, -NHR, -NRR, carboxamido, amido, carboxyl, carbonyl, or an amino acid residue; R₁ is hydrogen, acyl, -S(O)n-R, carboxyl, carbonyl, or an amino acid residue; each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heterocyclyl, halogen, -CN, -CF₃, -OR, -NHR, -NRR, or -NO₂; n is 0, 1, or 2; and each R is independently hydrogen, alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, or heterocyclyl.



Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:

5 June 2008